Q1 EPS Estimates for Haemonetics Decreased by Zacks Research

Haemonetics Co. (NYSE:HAE) – Stock analysts at Zacks Research decreased their Q1 2026 earnings estimates for Haemonetics in a research report issued to clients and investors on Thursday, June 5th. Zacks Research analyst R. Department now forecasts that the medical instruments supplier will post earnings of $1.01 per share for the quarter, down from their previous estimate of $1.03. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2026 earnings at $1.16 EPS, FY2026 earnings at $4.84 EPS, Q2 2027 earnings at $1.31 EPS, FY2027 earnings at $5.41 EPS and FY2028 earnings at $6.02 EPS.

Haemonetics (NYSE:HAE) last issued its earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. The business had revenue of $330.60 million during the quarter, compared to analysts’ expectations of $329.38 million. During the same period in the previous year, the company earned $0.90 earnings per share. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year.

HAE has been the subject of a number of other reports. Wall Street Zen lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. JMP Securities restated a “market outperform” rating and set a $100.00 target price on shares of Haemonetics in a research report on Tuesday, May 20th. Raymond James restated a “strong-buy” rating and set a $105.00 target price (down from $115.00) on shares of Haemonetics in a research report on Friday, May 9th. Finally, Needham & Company LLC reduced their price objective on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating for the company in a research note on Thursday, May 8th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Haemonetics has a consensus rating of “Moderate Buy” and an average price target of $97.89.

Haemonetics Stock Performance

Shares of HAE stock opened at $72.18 on Monday. The company has a 50 day moving average price of $64.42 and a 200-day moving average price of $69.40. Haemonetics has a 52 week low of $55.30 and a 52 week high of $94.99. The firm has a market capitalization of $3.47 billion, a PE ratio of 28.42, a P/E/G ratio of 1.11 and a beta of 0.36. The company has a quick ratio of 2.55, a current ratio of 3.97 and a debt-to-equity ratio of 1.35.

Hedge Funds Weigh In On Haemonetics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Arizona State Retirement System grew its stake in shares of Haemonetics by 1.2% in the 4th quarter. Arizona State Retirement System now owns 14,853 shares of the medical instruments supplier’s stock worth $1,160,000 after buying an additional 181 shares in the last quarter. Quarry LP lifted its holdings in shares of Haemonetics by 63.4% in the 1st quarter. Quarry LP now owns 495 shares of the medical instruments supplier’s stock worth $31,000 after acquiring an additional 192 shares during the last quarter. Louisiana State Employees Retirement System lifted its holdings in shares of Haemonetics by 1.4% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,100 shares of the medical instruments supplier’s stock worth $896,000 after acquiring an additional 200 shares during the last quarter. CWC Advisors LLC. lifted its holdings in shares of Haemonetics by 7.4% in the 4th quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier’s stock worth $241,000 after acquiring an additional 212 shares during the last quarter. Finally, Vise Technologies Inc. lifted its holdings in shares of Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier’s stock worth $221,000 after acquiring an additional 225 shares during the last quarter. 99.67% of the stock is owned by hedge funds and other institutional investors.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.